Lv2
180 积分 2025-09-27 加入
Polycystic ovary syndrome as a metabolic disease
7小时前
待确认
PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD
1个月前
已完结
PPAR control of metabolism and cardiovascular functions
1个月前
已完结
Insulin resistance: Review of the underlying molecular mechanisms
1个月前
已完结
Therapeutic inhibition of PPARα-HIF1α-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia
2个月前
已完结
The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study
2个月前
已完结
Pharmacokinetic Interaction of Chiglitazar with CYP3A4 Inducer or Inhibitor: An Open‐Label, Sequential Crossover, Self‐Control, 3‐Period Study in Healthy Chinese Volunteers
2个月前
已完结
Efficacy and safety of chiglitazar add‐on to metformin in type 2 diabetes mellitus ( RECAM study)
2个月前
已完结
Effect of chiglitazar and sitagliptin on glucose variations, insulin resistance and inflammatory-related biomarkers in untreated patients with type 2 diabetes
2个月前
已完结
Dapagliflozin and chiglitazar combination enhanced myocardial energy metabolism in high‐fat diet‐fed mice
2个月前
已完结
皖公网安备34019202002308
